以下文章来源于公募排排网 ，作者日月辉 公募排排网 . 这是一个每天都在想尽办法为你找到好基金的良心公众号。 本文首发于公众号"公募排排网"。 （点击↑↑ 上图查看详情 ） 创新药领衔医药板块 今年以来， 除了DeepSeek、机器人相关的科技板块走出了明显的大涨行情， 创新药领衔医药板块也悄悄走出了一轮结构性行情。 自2021年2 月的最高点以来，医药板块已经连续下跌了4年，调整幅度、时长均为历史之最。 公募排排网根据Choice整理的数据显示，截至今年5月23日，港股、A股5大主要医药医疗指数（ 中证医药、全指医药、医药 100、恒生医疗保 健、恒生港股通医疗保健指数 ）今年以来均实现上涨，其中 恒生医疗保健、恒生港股通医疗保健指数均涨超 30%。 然而，从估值来看，港股、A股5大主要医药医疗指数的 市盈率（ TTM，剔除负值，下同）百分位在6%-13%的区间内，这意味着它们的估值 仍然低于历史上超过80%的时间 。 其中，港股主要指数市盈率百分位不足10%，相对于A股市场主要指数更低。 首次 实现盈利 ，百济神州、诺诚健华等个股 亏损收窄 。 此外，今年以来，以 DeepSeek 为代表的人工智能技术取 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Views - The report highlights that the operating turning point for Guobang Pharmaceutical is evident, with the animal health business expected to contribute significantly to performance elasticity [5][13] - The pharmaceutical raw materials sector is maintaining a high level of prosperity due to upstream intermediate supply constraints and sustained post-pandemic demand [6][27] - The animal health raw materials sector is nearing the end of a market clearing phase, with prices for strong antibiotics showing a continuous recovery [7][42] Summary by Sections Guobang Pharmaceutical - Guobang Pharmaceutical has shown steady revenue growth, increasing from 4.206 billion in 2020 to 5.891 billion in 2024, with profits stabilizing around 800 million [13][14] - The gross margin for animal health raw materials has decreased significantly, reaching a historical low of 18.9% in 2024, while the gross margin for pharmaceutical raw materials has improved to 28.4% [17][19] - The company is experiencing a recovery in profitability, with gross margin, net margin, and ROE showing signs of improvement in 2024 [19][25] Pharmaceutical Raw Materials - The pharmaceutical raw materials segment, particularly macrolide antibiotics, is expected to maintain high profitability due to limited upstream supply and stable demand growth [6][27] - Key products include Azithromycin, Clarithromycin, and Roxithromycin, with the core raw material being thiocyanate erythromycin, which is crucial for production [27][30] Animal Health Raw Materials - The animal health raw materials market is stabilizing, with strong antibiotic prices recovering after a prolonged decline [7][42] - The market for strong antibiotics has shifted from over ten competitors to about three major players, with Guobang Pharmaceutical holding a significant market share [7][49] - The price of Florfenicol has dropped significantly from 500 RMB/kg in 2022 to around 180 RMB/kg in 2024, but is now showing signs of stabilization [7][50] Market Performance - In May, the pharmaceutical and biotechnology sector rose by 1.78%, outperforming the CSI 300 index by 1.96 percentage points, ranking first among 31 sub-industries [55][60] - The other biopharmaceutical sub-sector showed the highest growth, while the hospital sector experienced the largest decline [60][61]

2025.05. 24 本文字数：2099，阅读时长大约3分钟 Wind数据显示，在已经披露2024年年报的药企中，高管年薪在千万以上绝非个例。在俞德超之前， 还有多家药企的高管薪酬过亿。 作者 | 第一财经 陈敏之 近日，理想汽车（02015.HK/LI.US）创始人、董事长兼CEO李想2024年领取6.39亿元"天价年薪"冲 上热搜引发热议。 事实上，创新药企业里，也不乏上亿年薪的创始人和CEO，但有所不同的是，这些创新药公司多数 还没有走完商业化历程，公司处于连年亏损状态。比如刚刚敲钟上市的映恩生物（9606.HK），创 始人朱忠远去年薪酬8556万元，公司同期亏损超过10亿元。近期三次递表港交所的英矽智能，执行 董事任峰2024年薪酬总计307.3万美元，公司当年净亏损1709.6万美元。 这样例子在创新药企业里比比皆是。Wind数据显示，思路迪医药股份（1244.HK）董事长龚兆龙 2024年的薪酬为2067万元，六年的薪酬总额则超过5亿元，而公司六年亏损超40亿元。 高薪背后，是创新药行业整体尚未步出资本寒冬。高管的收入与公司业绩形成的强烈反差，引发市场 对行业价值导向的深度思考。 年薪千万比比皆 ...

Group 1 - The article highlights the stark contrast between high executive salaries and the financial performance of companies in the innovative drug sector, where many firms are still unprofitable [2][10][11] - Li Xiang, the founder and CEO of Li Auto, received a salary of 639 million RMB in 2024, sparking discussions about excessive executive compensation in the context of ongoing company losses [2][3] - Companies like InnoCare Pharma and Sihuan Pharmaceutical have reported significant executive salaries while simultaneously posting substantial losses, raising questions about the sustainability of such compensation structures [5][10] Group 2 - The article provides examples of high executive salaries in the innovative drug industry, including Zhu Zhongyuan of InnoCare Pharma with a salary of 85.56 million RMB in 2024, despite the company losing over 1 billion RMB [3][10] - Other notable salaries include Yu Dechao of Innovent Biologics, who earned approximately 136 million RMB, and Gong Zhaolong of Sihuan Pharmaceutical, whose total compensation exceeded 500 million RMB over six years [5][10] - The trend of high salaries persists even among companies that have not yet commercialized their products, such as Yingxi Intelligent and Weili Zhibo, which have reported significant losses [11]

Group 1 - The core viewpoint of the news is the performance and holdings of the Wanjiay Economic New Momentum Mixed C Fund, which has shown a decline in recent value but positive returns over longer periods [1] - As of May 23, 2025, the latest net value of the fund is 1.6007 yuan, reflecting a decrease of 1.79% [1] - The fund's one-month return is -4.46%, ranking 4362 out of 4480 in its category, while its six-month return is 22.90%, ranking 161 out of 4322, and its year-to-date return is 28.00%, ranking 90 out of 4372 [1] Group 2 - The top ten stock holdings of the Wanjiay Economic New Momentum Mixed C Fund account for a total of 75.95%, with significant positions in companies such as Ruixin Micro (9.12%), BeiGene-U (8.80%), and Deepin Technology (8.64%) [1] - The fund was established on February 7, 2018, and as of March 31, 2025, it has a total scale of 1.223 billion yuan [1] - The fund manager, Huang Xingliang, has a strong academic background with a Ph.D. from Tsinghua University and extensive experience in the investment management industry [2]

Group 1 - The core viewpoint of the news highlights the approval of a new innovative drug by Heng Rui Medicine, which is the first self-developed DPP-4 inhibitor combined with metformin in China, aimed at improving blood sugar control for adult patients with type 2 diabetes [1] - Following the announcement, Heng Rui Medicine's stock surged nearly 30% in the Hong Kong market, indicating strong investor confidence in the innovative drug sector [1] - The Hong Kong innovative drug index has seen a significant decrease in its price-to-earnings ratio from 64 times on February 21 to 25 times on May 22, suggesting a favorable investment opportunity in the sector [1] Group 2 - The Hong Kong innovative drug ETF (159567) tracks the National Index for Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends such as AI-enabled drug development and the expansion of domestic innovative drugs [2] - The larger innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from advancements in AI, the internationalization of domestic innovative drugs, and the introduction of new healthcare policies [2] - According to Xingye Securities, the innovative drug sector in China is transitioning from a "follower" to a "leader," with significant advancements expected in new targets and technologies by 2025, showcasing strong global competitiveness in areas like ADC, bispecific antibodies, and cell therapy [2]

Group 1 - The rise of ETF-FOF products is aimed at helping investors select suitable ETFs amidst a growing supply of ETF products, with several public fund institutions reporting such products this year [1] - The advantages of ETF-FOF products include higher capital efficiency, lower fees, and T+1 valuation disclosure, but they require enhanced macroeconomic research and asset allocation capabilities from public fund research teams [1] - The total issuance of science and technology innovation bonds in China's exchange bond market has reached 1.2 trillion yuan, with a significant increase in the number of strategic emerging industry companies listed [1] Group 2 - Securities firms are experiencing a new round of interest rate cuts, with customer margin interest rates dropping to as low as 0.05%, following banks' reductions in deposit rates [2] - The number of merger and acquisition exits involving PE/VC institutions has increased, with a 7.8% year-on-year rise in the first quarter of this year [2] - Several steel companies are actively investing in non-oriented silicon steel, driven by strong demand from home appliances and electric vehicles, indicating a balanced supply-demand situation in the industry [2] Group 3 - The camping economy in China is projected to reach a core market size of 213.97 billion yuan in 2024, with a year-on-year growth of 60.4%, and is expected to grow to 487.98 billion yuan by 2030 [3] - The price of polysilicon is stabilizing after a previous decline, with expectations that it will maintain its current price range for some time [4] - The global interest in small molecule drugs is increasing, with major pharmaceutical companies investing heavily in this area, indicating a competitive landscape for drug development [4] Group 4 - EV Electra plans to invest 1 billion USD in the restructuring of high-end automotive company, committing to a minimum of 100,000 vehicles or 3 billion USD in overseas procurement orders over the next three years [5] - Apple is reportedly planning to launch smart glasses by the end of 2026, aiming to capture a share of the AI device market [6] - Google is under investigation by the U.S. Department of Justice regarding its AI technology agreements, which may potentially violate antitrust laws [6]

智通财经APP获悉，截止5月22日收盘，有88只股票创52周新高，其中名仕快相(08483)、茂盛控股 (00022)、帝王实业控股(01950)创高率位于前3位，分别为67.60%、46.55%、45.71%。 | 南方东英越南３０ | 6.690 | 6.690 | 0.22% | | --- | --- | --- | --- | | (03004) | | | | | 诺诚健华(09969) | 10.960 | 11.320 | 0.18% | | 港灯－ＳＳ(02638) | 5.680 | 5.680 | 0.18% | | ESR(01821) | 12.860 | 12.860 | 0.16% | | 招商局港口(00144) | 14.320 | 14.460 | 0.14% | | 紫金矿业(02899) | 18.580 | 18.980 | 0.12% | | Ａ博时人民币－Ｒ | 1,059.000 | 1,059 | 0.05% | | (83192) | | | | | 工银南方国债(03199) | 115.400 | 115.400 | 0.04% | | Ａ博时港元(03 ...

Group 1 - The Hong Kong Innovation Drug ETF (159567) has experienced a year-to-date increase of 36.43% as of May 21, indicating strong performance in the biotech sector [2] - The ETF closely tracks the Hong Kong Stock Connect Innovation Drug Index (987018), which reflects the operational characteristics of listed biotech companies in Hong Kong [2] - The approval of China's first cross-border segmented production pilot project for innovative biological products marks a significant milestone, with Johnson & Johnson's drug being the first to receive such approval [2] Group 2 - Donghai Securities highlights that China's innovative drugs have advantages in low R&D costs and high efficiency, positioning the country as a potential center for low-cost R&D and production [2] - The transition from "generic following" to "innovation leading" is expected to accelerate, with multinational pharmaceutical companies seeking to reduce R&D and production costs under stricter pricing systems [2] - The CXO industry chain in China is likely to further solidify its market position as a result of these developments [2] Group 3 - According to Founder Securities, the systematic valuation uplift in the innovative drug sector is driven by the recognition of the business models of Chinese innovative drug companies [3] - Leading companies are entering profitability phases, and their R&D pipelines are beginning to generate regular income through business development (BD) [3] - The market is starting to assign more valuation premiums to drug companies' innovative pipelines, indicating a shift towards systematic valuation increases [3]

Group 1 - Heng Rui Medicine has set the final price for its H-share issuance at HKD 44.05 per share, with expected listing on May 23, 2025 [1] - Vanke A has signed a borrowing contract with Shenzhen Metro Group for RMB 4.2 billion, using up to RMB 6 billion of Wanwu Cloud stock as collateral [2] - Longqi Technology plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international competitiveness [3] Group 2 - Shanghai Laishi's controlling shareholder, Haiyingkang, plans to increase its stake in the company by investing between RMB 250 million and RMB 500 million [4] - Wangzi New Materials' controlling shareholder sold 1.11 million shares, accounting for 0.29% of the total share capital, amid the "controlled nuclear fusion" concept [5] - Huashi Technology's actual controller, Ye Jianbiao, has had his detention extended by three months, but the company's operations remain normal [6] Group 3 - Sichuan Gold's major shareholders plan to reduce their stakes by 2.5% and 3% respectively, citing personal funding needs [7] - Naxinwei has set the inquiry transfer price at RMB 163.15 per share, with full subscription from institutional investors [8] - Zhejiang Rongtai plans to invest RMB 20 million to establish a wholly-owned subsidiary focused on robotics [9] Group 4 - Kingood Co. has received a notification from a global leading automaker for a wheel product project in the U.S., with an estimated sales amount of approximately USD 158 million over five years [10] - Shanghai Xiba plans to purchase patents for hydrogen-electric hybrid power systems and solid-state lithium-ion battery technology, investing a total of RMB 25 million [11] - Nocare Biopharma's application for the market approval of Tafasitamab for treating relapsed/refractory DLBCL has been approved, marking a significant milestone in the market [12]